These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37570646)

  • 1. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z; Wang H; Ren H; Sun Y; Chen X
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
    Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM; Grothey A
    Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
    Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
    Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.
    Babaei A; Soleimanjahi H; Soleimani M; Arefian E
    Daru; 2020 Dec; 28(2):555-565. PubMed ID: 32803686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X; Wei Y; Wei X
    Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H; Clamor C; Müller K
    J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
    Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
    Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
    Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
    Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
    Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
    Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
    J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
    Leijten NM; Bakker P; Spaink HP; den Hertog J; Lemeer S
    Mol Cell Proteomics; 2021; 20():100033. PubMed ID: 33594990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
    Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
    Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression.
    Li JM; Hsu PC; Kuan FC; Shi CS; Yang CT
    Am J Cancer Res; 2022; 12(10):4637-4651. PubMed ID: 36381330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
    Hanafi M; Chen X; Neamati N
    J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
    Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.